Works matching IS 09395555 AND DT 2013 AND VI 92 AND IP 10


Results: 23
    1

    De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question".

    Published in:
    2013
    By:
    • Clavio, Marino;
    • Cruciani, Fabio;
    • Minetto, Paola;
    • Guolo, Fabio;
    • Ballerini, Filippo;
    • Marani, Carlo;
    • De Astis, Enrico;
    • Aquino, Sara;
    • Bergamaschi, Micaela;
    • Mitscheunig, Laura;
    • Grasso, Raffaella;
    • Colombo, Nicoletta;
    • Ghiggi, Chiara;
    • Lovera, Davide;
    • Pastori, Giordana;
    • Avenoso, Daniele;
    • Miglino, Maurizio;
    • Gobbi, Marco
    Publication type:
    journal article
    2
    3
    4
    5
    6
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17

    De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened 'GO question'.

    Published in:
    Annals of Hematology, 2013, v. 92, n. 10, p. 1309, doi. 10.1007/s00277-013-1780-7
    By:
    • Clavio, Marino;
    • Cruciani, Fabio;
    • Minetto, Paola;
    • Guolo, Fabio;
    • Ballerini, Filippo;
    • Marani, Carlo;
    • De Astis, Enrico;
    • Aquino, Sara;
    • Bergamaschi, Micaela;
    • Mitscheunig, Laura;
    • Grasso, Raffaella;
    • Colombo, Nicoletta;
    • Ghiggi, Chiara;
    • Lovera, Davide;
    • Pastori, Giordana;
    • Avenoso, Daniele;
    • Miglino, Maurizio;
    • Gobbi, Marco
    Publication type:
    Article
    18
    19
    20
    21
    22
    23